Reportify - AI Platform for Investment Research

Ge Long Hui· 2025-09-10 09:15

格隆汇9月10日丨阅文集团(00772.HK)公布，2025年9月10日，根据于2021年5月24日批准并于2023年5月 22日修订的2021年购股权计划行使购股权发行2.44万股。 ...

Ge Long Hui· 2025-09-10 09:15

Group 1 - The company, Neway Group (01686.HK), announced the issuance of 20,000 shares on September 10, 2025, based on the exercise of stock options granted under the stock option plan adopted on November 1, 2022 [1]

SUNEVISION(HK:01686)

绿地香港：1-8月实现合约销售约为人民币41.93亿元

Cai Jing Wang· 2025-09-10 09:15

公告显示，2025年首八个月，本公司、其子公司及其联属公司（统称 "本集团"）的合约销售约为人民币41.93亿元，已售合约总建筑面积则约为490,016平方米。 9月10日，绿地香港发布2025年1-8月未经审核营运数据。 ...

GREENLAND HK(HK:00337)

房地产开发

蔚来美股盘前跌超8%

Mei Ri Jing Ji Xin Wen· 2025-09-10 09:13

每经AI快讯，9月10日，蔚来美股盘前跌超8%。（文章来源：每日经济新闻） ...

哔哩哔哩美股盘前续涨超5% 上一交易日收涨近7%

Mei Ri Jing Ji Xin Wen· 2025-09-10 09:13

（文章来源：每日经济新闻）每经AI快讯，9月10日，哔哩哔哩美股盘前续涨超5%，上一交易日收涨近7%。 ...

招银国际：维持康方生物“买入”评级目标价182.12港元

Zhi Tong Cai Jing· 2025-09-10 09:12

Core Viewpoint - 招银国际 maintains a "Buy" rating for 康方生物 (09926), citing positive overall survival (OS) trends from the HARMONi trial, which enhances confidence in its first-line indication potential [1] Group 1: Clinical Trial Results - Summit released the latest data from the HARMONi global clinical trial, evaluating the efficacy of AK112 combined with chemotherapy versus chemotherapy alone in second-line EGFR-TKI resistant NSCLC patients [2] - Chinese patients demonstrated superior progression-free survival (PFS) results, with a median PFS of 6.8 months for AK112 combined with chemotherapy compared to 4.4 months for chemotherapy alone (HR=0.52, p<0.001) [3] - In long-term follow-up, the PFS HR slightly worsened to 0.57, potentially due to increased data maturity in Western populations, with North American and European patients showing PFS HRs of 0.67 and 0.55 respectively [3] Group 2: Overall Survival Analysis - In the final OS analysis, the median OS for the AK112 combined chemotherapy group was 16.8 months compared to 14.0 months for the chemotherapy alone group, with an HR of 0.79 (95% CI: 0.62–1.01, p=0.0570) [4] - Long-term follow-up showed an improvement in OS HR to 0.78 (95% CI: 0.62–0.98) with a nominal p-value of 0.0332, indicating a positive trend despite the FDA's reliance on pre-specified analysis results [4] - North American patients exhibited strong OS results with an HR of 0.70, although the confidence interval was wide (0.38–1.30) [5]